About: Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
Creator	Capra, Ruggero Cossi, Stefania De Rossi, Nicola Mattioli, Flavia Romanelli, Giuseppe Scarpazza, Cristina Sormani, Maria
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients’ mortality. METHODS: 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate ≥ 30 breaths/min, peripheral capillary oxygen saturation ≤ 93% or PaO2/FiO2<=300 mmHg. Patients admitted before March 13th (n=23) were prescribed the standard therapy (hydroxychloroquine, lopinavir and ritonavir) and were considered controls. On March 13th tocilizumab was available and patients admitted thereafter (n=62) received tocilizumab once within 4 days from admission, plus the standard care. RESULTS: Patients receiving tocilizumab showed significantly greater survival rate as compared to control patients (hazard ratio for death, 0.035; 95% confidence interval [CI], 0.004 to 0.347; p = 0.004), adjusting for baseline clinical characteristics. Two out of 62 patients of the tocilizumab group and 11 out of 23 in the control group died. 92% and 42.1% of the discharged patients in the tocilizumab and control group respectively, recovered. The respiratory function resulted improved in 64.8% of the observations in tocilizumab patients who were still hospitalized, whereas 100% of controls worsened and needed mechanical ventilation. No infections were reported. CONCLUSIONS: Tocilizumab results to have a positive impact if used early during Covid-19 pneumonia with severe respiratory syndrome in terms of increased survival and favorable clinical course.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1016/j.ejim.2020.05.009
bibo:pmid	32405160
has license	no-cc
sha1sum (hex)	00f14e01af3373cd33704ba23c31ee81acc9ef6b
schema:url	https://doi.org/10.1016/j.ejim.2020.05.009
resource representing a document's title	Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
has PubMed Central identifier	PMC7219361
has PubMed identifier	32405160
schema:publication	Eur J Intern Med
resource representing a document's body	covid:00f14e01af3373cd33704ba23c31ee81acc9ef6b#body_text
is schema:about of	named entity 'recovered' named entity 'min' named entity 'control' named entity 'hazard ratio' named entity 'Patients' named entity 'Hospital' named entity 'INFLAMMATION' named entity 'IMPACT' named entity 'MORTALITY' named entity 'ADJUSTING' covid:arg/00f14e01af3373cd33704ba23c31ee81acc9ef6b named entity 'monoclonal antibody' named entity 'function' named entity 'Patients' named entity 'mechanical ventilation' named entity 'patients' named entity 'Methods' named entity 'patients' named entity 'greater' named entity 'Italy' named entity 'severe' named entity 'baseline' named entity 'represents' named entity 'lopinavir' named entity 'receiving' named entity 'hydroxychloroquine' named entity 'respiratory function' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'tocilizumab' named entity '95% confidence interval' named entity 'respiratory rate' named entity 'monoclonal antibody' named entity 'tocilizumab' named entity 'clinical characteristics' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'mortality rate' named entity 'COVID-19' named entity 'RT-PCR' named entity 'oxygen saturation' named entity 'respiratory failure' named entity 'procalcitonin' named entity 'respiratory rate' named entity 'monoclonal antibody' named entity 'tocilizumab' named entity 'respiratory failure' named entity 'tocilizumab' named entity 'pneumonia' named entity 'mmc' named entity 'COVID-19' named entity 'CPAP' named entity 'severe or life-threatening' named entity 'COVID' named entity 'antiviral' named entity 'IL-6' named entity 'hypertension' named entity 'IL-6' named entity 'confidence intervals' named entity 'STROBE' named entity 'bacterial infections' named entity 'respiratory distress' named entity 'tocilizumab' named entity 'MERS' named entity 'heart disease' named entity 'tocilizumab' named entity 'diabetes' named entity 'tocilizumab' named entity 'survival rate' named entity 'hypertension' named entity 'immunological' named entity 'hypertension' named entity 'hydroxychloroquine' named entity 'neutrophils' named entity 'tocilizumab'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software